Palantir closes up 21% on report of $44 million FDA contract

A person wears a Palantir Technologies (PLTR) sweater outside the New York Stock Exchange (NYSE) on the day of their initial public offering (IPO) in Manhattan, New York City, U.S., September 30, 2020.

Andrew Kelly | Reuters

Shares of Palantir jumped more than 17% Monday after Bloomberg reported that the company won a three-year contract with the U.S. Food and Drug Administration.

The deal is worth $44.4 million and will focus on powering drug reviews and inspections, according to the report.

Co-founded in 2003 by tech investors Peter Thiel and Joe Lonsdale, CEO Alex Karp and others, Palantir provides data analytics software and services to government agencies and large companies. But its government work makes up more than half of its revenue, bringing in $163 million in its latest quarter.

The company said in November recent contracts it received during the third quarter include a $91 million deal with the U.S. Army, a $36 million contract with the National Institutes of Health $36 million and a $300 million renewal with an aerospace customer.

Palantir stock has surged nearly 200% since it went public Sept. 30.

Subscribe to CNBC on YouTube.

News

Articles You May Like

Redmi Pad SE Review: Budget Tablet With Good Battery Life
China-Linked Hackers Infiltrate East Asian Firm for 3 Years Using F5 Devices
Vivo Y58 5G Tipped to Launch Soon in India; Alleged Marketing Images Suggest Design, Specifications
Lessons from the Ticketmaster-Snowflake Breach
Learn to Secure Petabyte-Scale Data in a Webinar with Industry Titans

Leave a Reply

Your email address will not be published. Required fields are marked *